newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - NEKTAR THERAPEUTICS

All right. Welcome, everyone, to 2026 Jeffries Global Healthcare Conference in London. My name is Roger Song, senior and I cover Semicat Biotech in the U.S. It is my pleasure to have a five-star chat with our company, Nectar Therapeutics, Jay-Z, the head of R&D, with me today. So, Jay, why not you start with some very high-level overview of Necta? What where you are now, and then where you're heading to, and then we can talk some of the details about your pipeline. Sure, and thank you very much, Roger, and thank you to Jeffries for the invite to the conference this year. We're very pleased to be here. At Nectar, we've been really focusing on our experience in immune regulation and understanding how to address indications in the INI spectrum. We've been focused on the Treg targeting space, or regulatory T-cells. You know, very topical, as it was the subject of last year's Nobel Prize, the discovery of immune tolerance, as well as the discovery of Tregs to doctors Sakaguchi, Ramsdell, and Brook now. We've been working on a molecule called RESPEG-Aldisleukin, which is, to our knowledge, the most advanced regulatory T cell targeting agent. We've recently posted very strong phase two data in two different indications with RESPEG. The first of these was in patients with moderate to severe atopic dermatitis, where we showed RESPEC in a dose-dependent fashion could induce a very rapid resolution of significant disease symptoms, such as itch and skin clearance. And then with repeated dosing out to 52 weeks, we saw patients continue to not just achieve and keep their response, but continue to improve on the quality of that response. One of the things we observed in our 52-week maintenance was that patients treated up to a year, one in three people actually achieved an easy 100 score or complete skin clearance. And we were able to achieve that on a once a quarter or every 12-week dosing regimen. So things that really started to differentiate RASPEG as a novel mechanism of action, as a kind of an agent where the effect builds up with time, great durability of the response, and some very deep efficacy benchmarks that were reached at one year. We followed that up with a study in patients with severe to very severe alopecia areata, where we saw patients treated through 52 weeks were able to achieve efficacy right in line with a JAK inhibitor that we used the Illumiant benchmark to guide to our TPP. we were able to achieve that aluminum bar but then we saw this other very important feature of respeg's mechanism in that after one year of treatment we followed patients for six months off drug and the purpose was to assess durability of the hair the patients regrew because we knew in this field patients treated with the jack inhibitor could grow hair but when they stopped the jack inhibitor they lost their hair and we saw the majority of people not just keep their hair but many people continued to grow additional hair in the six months off drug. And we saw the SALT10 score, which is 90% or greater hair regrowth of their scalp, that rate actually tripled over the six-month off drug period. So when we take a step back and we think about the novelty of a regulatory T-cell mechanism, the ability for ResPeg to consistently control regulatory T-cel pharmacology and to achieve all of the kind of clinical pharmacology needs that you need when you administer a biologic to patients chronically and the kindof benchmarks we've hit across these indications that makes us very excited about our positioning. And to that end, we've just kicked off the Phase III Registrational Program for RESPEG and atopic dermatitis. Three pivotal studies, all of them are underway. That whole program kicked off in the summer of 2026. And in the coming weeks, in December of this year, we'll kick off the registrational program of ResPag and Alopecia areata, all building on this phase two results that I just mentioned and being really a very exciting time for Nectar. We'll expect the first of the top line readouts from the phase three in the middle of 2028. Excellent. Thanks, JT. Logging on, and then I have to resonate with the novelty of the TREC because we follow pretty closely the atop dermatitis and the entire INI space. Not many times we will see those real new mechanism with a very interesting property and the profile. Okay, let's dive in on the atopic dermatitis. So the next data update actually is the 1Q next year. you have 52 weeks of treatment after the one-year maintenance. Tell us a little bit more about the design because you are benchmarked to the DUPI 50%-ish, kind of nine months of treatment on the maintenance withdrawal. So what's the difference and the similarity compared to that benchmark? And then I'll have some specifics. Yeah, sure. So firstly, just to sort of set the table, we've observed with RESPEG from even our earliest Phase I study that there was a unique off-drug durability to the mechanism. And just briefly, you know, to remind everyone, we did a small phase one study where we treated about 40 patients in the whole trial. But we treated for 12 weeks with ResPeg, and then we followed people for nine months off-druck. And it was a true observation. You know, we just followed patients. They would come back to the clinic with no additional treatment of any kind. And we saw very deep durability of response. both for EZ-75 and the IGA, and that maintenance was maintained for nine months. So that was an interesting observation in a small Phase I study, and we wanted to be more prospective about assessing that as a differentiating feature of the mechanism. So in the Phase II, we built in a one-year off-drug observation after patients were treated for one year in the atopic dermatitis setting. And so I commented on the efficacy benchmarks we hit at one year of treatment. And now in this off-drug period, there will be about 125 people that completed, you know, the 52-week treatment in the phase two. Of those, 15 are on placebo and 110 are on drug. The placebo people and others were there to maintain the blind, even though it was just an observation. It was still blinded, you Know, to the investigators and to the patients. the way the study was designed is we basically have quarterly disease assessments so there's there's in total five one month follow-up followed by quarterly assessments afterwards out to one year and this really gives us a chance to look at what happened after one year of treatment now looking at one year off drug durability and we'll look to see if patients that reach their response how well they could maintain it and also if there was any improvement or deepening of response off drug as well. There really aren't a lot of benchmarks, you know, for this because this is such a novel sort of element and novel way to even approach, you know observing a drug in this patient population. But there are a couple of benchmarks that we're going to key into. In a number of phase three studies when a maintenance regimen is tested the health authorities often ask for a withdrawal kind of component. So for example with dupixin in the solo continue they tested after induction re-randomizing patients to either stay on a treatment of dupixent or move on to a sham injection of placebo so in that setting even people that are on placebo they don't know they're on placebo is it's a randomized withdrawal they are getting an injection they just don't Know if it's drug or placebo and under those conditions over a nine-month period, Dupixent demonstrated about a 50% maintenance of EZ-75 across that nine- month period with the placebo withdrawal and the sham injections. So our study, again, is different because there is no sham injection. It's just a direct observation. But the closest benchmark is that Dupitzent analog, and that's why we were discussing a 50%. So Dupizent hit that at nine months. Our study is 12 months. So if we reach that point at 12 months or even exceed it, you know, we think that'll be very notable. And, you know based on some of our early data that I mentioned, I think it's quite reasonable that we could do that. Excellent. Clarification on the 125 patient, are they all ED75 responder? And then how about the DUPI-R, DUPi-Withdrawal cohort? Yeah, so that's the patients that completed. Not all of those patients will be easy 75 responders so when we look at maintenance we will be looking at the population or proportion that were responders then you're assessing maintenance because you have to have a response in order to assess maintenance of that response so the dupy number is the maintenance of easy 75. okay yeah yeah okay um and then the other thing is the um you know for those patients into the risk maintenance is 50, I believe. And then it goes into the maintenance. How much selection bias do you think you will have for those 125? Well, I mean, it's really the patient population that, you know, continued through the study, right? So, I means, it is also indicative of the regimen, right? Because our whole kind of objective with all of these approaches besides the differentiation is really to define the regime, right. And so, one of the ways you could think about it is there's an induction regimen, which with RESPEG will be a twice a month dosage. We expect that for a period of six months, and that's how we design the phase three. Then patients will move into maintenance on either a monthly or a quarterly regimen. But then you could imagine if we see durability off drug as we think we will based on our phase one, then, for example, all patients could move to a once-a-quarter maintenance, you know, from years one onward. And those would be some of the very unique ways and highly differentiating for this class because right now Dupixent is a drug that people take twice a month in perpetuity. Got it. And then, so, for the 52 weeks off treatment period, how would you handle those people drop off and then use rescue medicine? They will automatically become a non-responder, just a loose there? Yeah. So firstly, like rescue medicine use in general has been really low in this trial. And we just published the Lancet. In the Lancets, the results of the induction. We're actually will be submitting the resultsof the maintenance very soon as well. And we've seen across the board just very low rescue med usage, which I think reflects, you know, the quality of the responses that patients are seeing when they're on ResPeg. And then in terms of how you handle it, But, you know, again, this is an interesting study because even the Dupixent analogs, all of those people had access to extension studies, you know, later. So there's always sort of a chance for additional treatment. But in our study, there isn't. People are just observed. And so you kind of have a few different ways you can look at that. So you can looking at the response that people have if they discontinue and when. Because, again there's not a lot of other than sort of the patient's altruism. you know they're off the study so for them to come back to the study side is really just you know them participating in the study there's no kind of impetus you know for them otherwise but we can look at things like the last observation carried forward for example to look at the response if a patient discontinues and to correlate anything related to their discontinuation relative to efficacy at that time so we'll look at a number of different ways and and even if you um review some of the literature like the solo continue trial from Dupixent that I'm mentioning, you can even see that they use multiple methodologies to handle patient dropouts and patient dispositions through that nine-month randomized withdrawal period. And then so because those patients are not all EZ-75 at the end of maintenance, and then when you report at the end of 25 52 weeks off treatment you will measure either 75 or 50 so what will be considered as a responder yeah i think a good kind of comparison similar to how we reported our maintenance data so we'll look at people that had a response whether it's 50 75 90 iga or itch and then we'll look at the maintenance or even easy 100 and we'll Look at the Maintenance of that response But then we'll also look at people that didn't have a response, did they gain, right? And then looking, for example, we also reported the overall response rate, such as for IgA and EZ100. So these are all very reasonable, you know, ways to look at the data. And they'll allow us to capture all of the elements of the mechanism. And, of course, this is off-drug, right, so there's no more dosing, right. It's really just looking at the efficacy. And then probably more fair benchmark to the DUPI withdrawal randomizer withdrawal, 50% is the patient at the end of maintenance, they are reaching ED75, and then you look at how many percentage of those maintain the ED75. That's probably it. Yeah, that's like the true definition of maintenance. So these are the people that had the response at time zero, and dann how long did they keep that response over time? That's right. And because, as you said, 2P is kind of a, they have a sham, kind of placebo, and then also they know they're going to get access to the extension. How much of the 50% will be inflated or deflated compared to your design? Yeah, I mean, I think it's a great, great question, and we'll report the results when they come. The other kind of, I guess, sort of maybe parallel is there was a small phase two study that RoCAD to Linumab did in their phase two, not in their face three. but there they treated people with the ox 40 you know depleting antibody for 36 weeks and then they had a 20 week off drug observation so much shorter you know period of time than of course we're doing and even shorter than our phase one study they saw some durability but there was quite a bit of erosion of efficacy in that study but of course that's a different mechanism of action for us like that's an important comparator because the study design is similar but it's the less relevant benchmark because that drug never made it right whereas we see dupixin is more relevant it's by far you know it's THE drug that sells the most in atopic dermatitis there's the most experience with it and it's really the best understood mechanism. Okay yeah we've spent a fair amount of time on this because this is more near-term catalyst or the data because a lot of the But because the design of the study a little bit, you know, explanation is needed. Okay, let's quickly on the couple other things related to the atopic dermatitis. You also give us some updates on the phase 3 design, AD2. So you will add the design, the redesign as the topical corticosteroid add-on. So what, you Know, I know you're talking about a global regulator and then they want to see some add-ons results. how much the input from the FDA and the EMA for this design, and did they ask you to do that, and how you will change your regulatory strategy in the U.S. and in Europe? Yeah, I mean, I think that sort of capturing the global usage of systemic drugs and in different regions, kind of the desire and necessity to combine them, a topical corticosteroid, was definitely a driver. But for us, at the end of the day, this is really good news because this gives us the chance to develop really the most aggressive and differentiated label opportunity for ResPag because there's essentially all of the uses you could imagine would be a monotherapy in the biologic naive patient population, which is the patient population in our Zenith AD1 trial. We're prospectively testing monotherapy in patients that have failed a biologic and or a JAK inhibitor. It's very novel. I mean, we're going to, you know, prospectively test that in this patient population. That's the design of Zenith AD3. That gives a clear differentiating label for the second line plus. And then since topical corticosteroid combination is really commonly used in many, many regions, the design in ZenithAD2 is adding on the topical courticosteroids. So it's TCS plus placebo versus TCS плюс RESPEG. And that's in the mixed patient population of both naive and biologic experienced and or JAG experienced patients. So when you take a step back, that's basically every use category, you know, covered for RESPEG. And it gives us, again, a very exciting label that can be very differentiated relative to the competition. And then because it is add-on, I don't believe you changed the sample size. How's the power change with the design change? Yeah, it's still very, very high because there's 510 patients that we enroll in each of these three studies. And if you look historically at TCS studies, there is a little bit of an increase in the placebo, but there's also an increase on the drug arm, and you still see very high separation. So within our power calculations and others, this is a very well-powered study. We're very confident about the design. Any change recently for the topical steroid, corticosteroid performance at the placebo? And across different endpoints, I believe E75 is slightly different from the IgA 0 and 1. Well, I mean, yeah, so all patients get drug, right, in those studies. So you do see a little bit of difference. But like I said, when we've looked across the results for DUPI, for LEBRI, for nemolizumab, which is all on topical combination anyway, you continue to see the separation. And certainly in our preclinical studies, we combined both a TCS and a TCI with RESPEG in a range of different dermatitis models, and the effect was at least additive. In many cases, it was actually highly synergistic. In fact, in many of those models, we could back way down on the dose of the steroid and still see the benefit of the combination. Got it. And then just last question on the AD, because as we said earlier, it's a very active space, and then you do have, you know, along the TH2 kind of pathway, you continue to evolve in, you know, different ways to address the IL-13, IL-2, no, the IL4, and then also you have a little bit novel oral and then some of the other mechanism still along the same kind of path way. How do I think a RESPAC can fit into the future AD space and then what's your feedback you're getting from your physician advisors? And I do notice you have some benefit on the comorbidity, including asthma, so would that be required or meaningful differentiator for the RESPAT? Yeah, I mean, we think yes to many of the things that you raised. I think I'll sort of start off with as the R&D guy. One thing that was really exciting we demonstrated at EADV, a series of proteomic and transcriptomic analyses both from skin samples collected of lesional atopic dermatitis, you know, lesions that were stripped with the tape, and also systemically by measuring serum, that as early as week two, after just a single dose of Respag, we were able to begin normalization of multiple systemic and local immunological pathways that are beyond th2 so we saw th1 th2 th17 pathways normalizing after just a single dose as well as fibrotic signatures and even other disease associated signatures around cardiac health and other kinds of immunological fitness so what that starts to demonstrate for us is a clear separation that systemically the immunological dysfunction that the patient has starts to reverse as early as a single dose even faster than you see skin clearance even faster then you see itch and other relief so that means that respag has this fundamental different way right that it can start to heal the patient's immune system that we think now reflects the different sort of clinical properties that we're seeing with the respag mechanism. One of those is the dual efficacy in the comorbidity of patients that have asthma and atopic derm at the same time. Only Dupixent has been able to treat both until our data in phase two demonstrating that ResPeg also reaches that same benchmark and is able to really profoundly, you know, reduce the asthma patient reported outcome issues that the patients are facing, with both severe uncontrolled as well as any asthma at all. We also mentioned in an earlier earnings call that patients with rhinosinusitis also demonstrated a benefit, and we'll be presenting that data at a medical meeting in 2027, the early part of the year, and that'll capture both rhinos sinusitis as well co-morbidity of allergy and rhinos sinusitis. So that's a second element. And then the third element is something we've been talking about before, that the durability that comes from fixing the immune dysfunction has a great effect on the symptoms, but we think is really modifying the underlying pathology of the disease, which then reflects to very low frequency dose interval and, you know, potentially longer and longer periods of durability after the cessation of treatment. All of these things, we think, position RESPAG in a very unique way to come in as a new MOA that can be very disruptive in this field. Okay, great. We don't have much time left, but the focus was the atopic dermatitis. But alopecia areata, you're also moving to the phase three. One thing I just want to highlight is you did not include any JAK inhibitor in the phase two, similar to the AD, but you separate the biologic JAK experience in the 90-year patient for the AD phase 3, but you combine them in the alopecia areata. So how many patients do you expect will enroll for those prior JAK, and then how you think you're going to impact the overall outcome? Would you stratify that? Yeah, so, I mean, you know, we haven't guided to any of the specifics around that yet, but it'll be what regulators want to see as a representative patient population. And so representative means that, like, what would it be in real world? Well, in real World, some people take JAK inhibitors, but it's still a minority, right? The majority of patients are actually untreated with a JAK. So in our study, you know, we'd expect the majority of patience to be naive, you know, by far. We also, when we thought through putting that together, you know, we don't see an issue or a risk of a patient that's a prior JAK inhibitor patient, because generally these are people that have lost their hair, right? And so we want to give them the opportunity to regrow it, since the JAK Inhibitor that they had to discontinue, for most people that will be for toxicity reasons, right, was definitely holding back their progress, and we hope Respec can help them. The other kind of key point for us is that the health authorities gave us the guidance that we can use a single phase 3 study to support that registrational approval and so that study that kicks off for us next month will be an 850 patient trial in adolescents age 12 and up with a mixed population of naive and jack experienced patients and we expect data in 2029 from that study. Action. Thank you J.D. Thank you everyone.

Company
NEKTAR THERAPEUTICS
Keywords
NEKTAR THERAPEUTICS